JAZZ PHARMACEUTICALS ANNOUNCES EUROPEAN COMMISSION MARKETING APPROVAL OF XYREM

Jazz Pharmaceuticals, Inc. announced today that the European Commission has granted marketing approval in the European Union of Xyrem(R) (sodium oxybate) oral solution for the treatment of cataplexy in adult patients with narcolepsy. Xyrem is marketed in the European Union by UCB, which today announced the product's availability in Germany.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-08-2005/0004230737&EDATE=)